Service d'Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France.
Service d'Anesthésie-Réanimation, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France; Laboratoire CarMeN, INSERM1060, Faculté de Médecine Lyon Est, Lyon, France.
J Cardiothorac Vasc Anesth. 2022 Aug;36(8 Pt B):2864-2869. doi: 10.1053/j.jvca.2022.02.016. Epub 2022 Feb 14.
Postoperative atrial fibrillation (POAF) is a major complication after cardiac surgery, and an early postoperative introduction of beta-blockers is recommended to reduce its incidence. Landiolol, a new intravenous short-acting beta-1 blocker, could present a useful and safe macrohemodynamic profile after cardiac surgery. Detailed metabolic and hemodynamic effects of landiolol on cardiac performance, however, remain poorly documented. The authors aimed to investigate the dose-dependent hemodynamic and metabolic effects of landiolol in that specific setting.
A prospective, randomized, double-blind study versus placebo.
A tertiary university hospital.
Adult patients scheduled for elective cardiac surgery with cardiopulmonary bypass.
Incremental doses of intravenous landiolol (0.5, 1, 2, 5, and 10 μg/kg/min) were given within the 2 hours after arrival in the intensive care unit. Macrocirculatory parameters and cardiac performances were derived from transpulmonary thermodilution and transthoracic echocardiography. Metabolic data were obtained from arterial blood tests.
From January to November 2019, 58 patients were analyzed and divided into a landiolol group (n = 30) and a control group (n = 28). Heart rate significantly decreased in the landiolol group (p < 0.01), whereas mean arterial pressure and stroke volume remained unchanged. No significant modification was found in both left and right systolic and diastolic performances. Metabolic variables were similar in both groups. New-onset POAF occurred in 9 (32%) versus 5 (17%) patients in the control and landiolol groups, respectively (p = 0.28).
Infusion of landiolol in the range of 0.5-to-10 μg/kg/min during the early postoperative period presents a good macrohemodynamic safety profile in cardiac surgical patients and could be useful to prevent POAF.
心脏手术后的心房颤动(POAF)是一种主要的并发症,建议在手术后早期引入β受体阻滞剂以降低其发生率。兰地洛尔是一种新型的静脉内短效β-1受体阻滞剂,在心脏手术后可能具有有用且安全的宏观血液动力学特征。然而,兰地洛尔对心脏功能的代谢和血液动力学影响的详细信息仍记录甚少。作者旨在研究该药物在特定环境下剂量依赖性的血液动力学和代谢作用。
前瞻性、随机、双盲对照研究,与安慰剂进行比较。
三级大学医院。
择期行体外循环心脏手术的成年患者。
在到达重症监护病房的 2 小时内,给予递增剂量的静脉内兰地洛尔(0.5、1、2、5 和 10μg/kg/min)。宏观循环参数和心脏功能从经肺热稀释法和经胸超声心动图获得。代谢数据从动脉血检测中获得。
2019 年 1 月至 11 月,分析了 58 例患者,并将其分为兰地洛尔组(n=30)和对照组(n=28)。兰地洛尔组的心率显著降低(p<0.01),而平均动脉压和每搏量保持不变。左右心室收缩和舒张功能均未发现明显改变。两组的代谢变量相似。对照组和兰地洛尔组新发 POAF 的患者分别为 9 例(32%)和 5 例(17%)(p=0.28)。
在心脏外科手术后早期,以 0.5 至 10μg/kg/min 的剂量输注兰地洛尔具有良好的宏观血液动力学安全性特征,可用于预防 POAF。